Lancet Child & Adolescent Health最新文献

{"title":"The Lancet Child & Adolescent Health Commission on the future of neonatology","authors":"Prof Daniele De Luca PhD ,&nbsp;Prof Neena Modi FMedSci ,&nbsp;Prof Peter Davis MD ,&nbsp;Prof Satoshi Kusuda PhD ,&nbsp;Prof Saskia N de Wildt PhD ,&nbsp;Prof Martin Keszler MD ,&nbsp;Allyah Abbas-Hanif MD ,&nbsp;Prof Sandra E Juul PhD ,&nbsp;Prof Mark Turner PhD ,&nbsp;Prof J Jane Pillow PhD ,&nbsp;Prof Nikki Robertson PhD ,&nbsp;Prof Manuel Sanchez-Luna PhD ,&nbsp;Prof David G Tingay PhD ,&nbsp;Prof Alexandra Benachi PhD ,&nbsp;Flavia Bustreo MD ,&nbsp;Gianluca Ianiro MD ,&nbsp;Prof Mark Hanson PhD ,&nbsp;Prof Jan Deprest PhD ,&nbsp;Prof Paolo De Coppi PhD ,&nbsp;Agnes van den Hoogen PhD ,&nbsp;Prof Steven H Abman MD","doi":"10.1016/S2352-4642(25)00106-3","DOIUrl":"10.1016/S2352-4642(25)00106-3","url":null,"abstract":"<div><div>Neonatal mortality remains unacceptably high throughout the world. Survival of sick infants in their first month of life has improved over the past six decades. However, many comorbidities persist, with lifelong implications for health. The current ecosystem for research and development of drugs and medical devices to treat neonatal disorders is hindering further improvements to neonatal outcomes, especially infants born preterm or needing critical care. Innovation is lagging, and this is a public health problem characterised by multifactorial challenges in leadership, collaboration, regulation, funding, and commercial viability. The <em>Lancet Child &amp; Adolescent Health</em> Commission on the future of neonatology was created to consider these challenges and design a roadmap of strategies to accelerate research and development that will innovate and improve health care for neonates. We call for regulatory agencies, governments, funders, industry partners, and clinical researchers from diverse medical fields to invest in effective pathways for drug and medical device development and to unite in responsive and dynamic collaborations with diverse patients, families, and advocacy groups whose engagement in clinical research and advocacy can help neonatologists to achieve the best science and health equity for neonates worldwide, now and in the future.</div></div>","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 8","pages":"Pages 578-612"},"PeriodicalIF":19.9,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144503995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term kidney outcomes in children and adolescents with hypertension: a propensity-matched cohort study","authors":"Junayd Hussain MSc ,&nbsp;Kalina Georgieva BHK ,&nbsp;Cal H Robinson MD ,&nbsp;Nivethika Jeyakumar MSc ,&nbsp;Graham Smith PhD ,&nbsp;Prof Tammy Brady MD PhD ,&nbsp;Allison Dart MD MSc ,&nbsp;Janis Dionne MD ,&nbsp;Sabine Karam MD ,&nbsp;Ashlene M McKay MD ,&nbsp;Prof Rulan Parekh MD MSc ,&nbsp;Rukshana Shroff MD PhD ,&nbsp;Prof Manish D Sinha MBBS PhD ,&nbsp;Andrew M South MD MSc ,&nbsp;Carol Vincent MD MSc ,&nbsp;Prof Manish M Sood MD MSc ,&nbsp;Rahul Chanchlani MD MSc","doi":"10.1016/S2352-4642(25)00127-0","DOIUrl":"10.1016/S2352-4642(25)00127-0","url":null,"abstract":"<div><h3>Background</h3><div>Hypertension affects 6% of all children and adolescents, is increasing in prevalence, and is associated with adverse cardiovascular outcomes. In childhood chronic kidney disease, hypertension is associated with progression to kidney failure. However, direct evidence linking childhood hypertension with long-term adverse kidney outcomes is scarce. We aimed to determine the long-term risk of major adverse kidney events (MAKEs) among children and adolescents diagnosed with hypertension.</div></div><div><h3>Methods</h3><div>In this population-based retrospective cohort study, we assessed data from all children and adolescents (aged 3–18 years) diagnosed with hypertension from April 1, 1996, to March 31, 2023, in Ontario, Canada, using validated case definitions in health administrative databases. Each case was propensity score-matched with up to five controls without hypertension by age, sex, birthweight, maternal gestational hypertension, pre-existing diabetes, previous cardiovascular surgery, obesity, previous acute kidney injury, and a propensity score for hypertension diagnosis. The primary outcome was major adverse kidney events (MAKEs; ie, all-cause mortality, incident chronic kidney disease, or kidney failure defined as start of chronic dialysis or receipt of kidney transplantation), assessed using weighted Cox regression using robust variance estimators to estimate hazard ratios (HRs) and 95% CIs.</div></div><div><h3>Findings</h3><div>26 324 children and adolescents with hypertension were matched with 126 834 controls without hypertension, who were balanced on baseline covariates by propensity score matching. For children and adolescents with hypertension, median age at entry was 15 years (IQR 12–17), there were 10 868 (41·3%) females and 15 456 (58·7%) males, and previous personal and maternal comorbidities were uncommon (1169 [4·4%] had congenital heart disease, 1787 [6·8%] malignancy, 432 [1·6%] diabetes, 2356 [9·0%] complex chronic conditions, and 379 [3·0%] born to mothers with hypertension). During a median 14·2-year follow-up (IQR 7·4–20·7) in the hypertension cohort and 13·7-year follow-up (7·1–21·2) among controls, MAKE incidence was 5·52 per 1000 person-years (95% CI 5·28–5·76) in children and adolescents with hypertension versus 1·66 per 1000 person-years (1·60–1·72) in matched non-hypertensive controls (7·7% <em>vs</em> 2·4%; HR 3·03 [95% CI 2·86–3·21]).</div></div><div><h3>Interpretation</h3><div>Children and adolescents diagnosed with hypertension are at greater long-term risk of MAKEs compared with non-hypertensive controls. Improved recognition and control of paediatric hypertension might prevent progressive kidney dysfunction. These findings should be confirmed by large-scale, well-controlled prospective studies.</div></div><div><h3>Funding</h3><div>Department of Pediatrics at McMaster University.</div></div>","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 8","pages":"Pages 553-564"},"PeriodicalIF":19.9,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144503996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and predictions to 2030 in demographic structures and metabolic health for children and adolescents in China: analysis of national school health surveys from 2000 to 2019","authors":"Xinli Song PhD ,&nbsp;Bin Zhou PhD ,&nbsp;Prof Sarah Baird PhD ,&nbsp;Prof Chunling Lu PhD ,&nbsp;Zhiying Song PhD ,&nbsp;Yi Zhang PhD ,&nbsp;Ruolin Wang PhD ,&nbsp;Jianuo Jiang MS PhD ,&nbsp;Li Chen PhD ,&nbsp;Jieyu Liu PhD ,&nbsp;Wen Yuan PhD ,&nbsp;Yunfei Liu PhD ,&nbsp;Jiajia Dang PhD ,&nbsp;Peijin Hu PhD ,&nbsp;Prof Jun Ma PhD ,&nbsp;Prof Yanhui Dong PhD ,&nbsp;Prof Yi Song PhD ,&nbsp;Majid Ezzati FMedSci ,&nbsp;Prof Susan M Sawyer MD","doi":"10.1016/S2352-4642(25)00140-3","DOIUrl":"10.1016/S2352-4642(25)00140-3","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Understanding the changing metabolic health burden among children and adolescents is crucial for current and future public health resource allocation in China, particularly given rapid population ageing. We aimed to estimate trends in the metabolic burden in children and adolescents aged 7–18 years from 2000 to 2030, using overweight, obesity, and hypertension as proxy indicators.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We extracted age, sex, height, weight, and blood pressure data for Han children and adolescents aged 7–18 years, as recorded in five cycles of the Chinese National Surveys on Students Constitution and Health in the years 2000, 2005, 2010, 2014, and 2019. We used demographic indicators reported by the Seventh National Population Census in 2020 to represent the demographic situation in 2019 and UN population estimates and projections for China to derive the national age structure from 2000 to 2030. We calculated the 2019 age-standardised prevalence rates of overweight and obesity, hypertension, comorbid overweight and obesity with hypertension, severe obesity, and severe hypertension. Direct standardisation was applied to adjust for the effect of changes in population structures and derive age-specific prevalence estimates from 2000 to 2030. A population development index that captures demographic trends while accounting for the influence of age structure was calculated from birth rate, death rate, and proportions of the population aged 0–14 years and older than 65 years. Correlation coefficients (&lt;em&gt;r&lt;/em&gt;) and corresponding p values for the association between the population development index and metabolic burden were calculated with general linear regression models. Multinomial regressions were applied to model age-specific and sex-specific prevalence rates as a function of time. We used decomposition analysis to evaluate the individual contributions of age-specific prevalence, age distribution, and population growth to the net change in case numbers.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;The final analysis of national survey data included 1 106 416 observations. In 2019, the age-standardised prevalence rates were 21·5% (95% CI 21·3–21·7) for overweight and obesity, 16·6% (16·4–16·8) for hypertension, 5·5% (5·4–5·6) for overweight and obesity with hypertension, 1·6% (1·5–1·6) for severe obesity, and 2·1% (2·0–2·2) for severe hypertension. China's population of children and adolescents aged 7–18 years is predicted to decrease from 276 million in 2000 to 181 million in 2030 (–34·4%). Between 2000 and 2030, we estimate increases of 39·0 million (180·6%) cases of overweight and obesity, 7·1 million (131·5%) cases of overweight and obesity with hypertension, 4·3 million (430·0%) cases of severe obesity, and 1·2 million (34·3%) cases of severe hypertension. Between 2000 and 2030, we estimate a slight decrease of 0·3 million (–0·8%) cases of hypertension. A significant negative association between population d","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 8","pages":"Pages 530-543"},"PeriodicalIF":19.9,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144335591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and challenges in childhood pneumonia","authors":"The Lancet Child & Adolescent Health","doi":"10.1016/S2352-4642(25)00162-2","DOIUrl":"10.1016/S2352-4642(25)00162-2","url":null,"abstract":"","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 7","pages":"Page 439"},"PeriodicalIF":19.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study","authors":"Timothy E Dribin MD ,&nbsp;Prof Hugh A Sampson MD ,&nbsp;Yin Zhang MS ,&nbsp;Stephanie Boyd PhD ,&nbsp;Prof Nanhua Zhang PhD ,&nbsp;Kenneth A Michelson MD ,&nbsp;Prof Mark I Neuman MD ,&nbsp;Prof David C Brousseau MD ,&nbsp;Prof Rakesh D Mistry MD ,&nbsp;Prof Stephen B Freedman MDCM ,&nbsp;Prof Paul L Aronson MD ,&nbsp;Kelly R Bergmann DO ,&nbsp;Brittany Boswell MD ,&nbsp;Sri S Chinta MBBS ,&nbsp;Wee-Jhong Chua MD ,&nbsp;Ari R Cohen MD ,&nbsp;Joanna S Cohen MD ,&nbsp;Alicia Daggett MD ,&nbsp;Justin R Davis MD ,&nbsp;Julia F Freeman MD ,&nbsp;Seth Woolf","doi":"10.1016/S2352-4642(25)00139-7","DOIUrl":"10.1016/S2352-4642(25)00139-7","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Children presenting to the emergency department with anaphylaxis typically receive at least one dose of epinephrine and are observed in the emergency department or monitored for recurrent (biphasic anaphylaxis) or persistent symptoms on hospital wards for variable durations before discharge is considered safe. We aimed to calculate the incidence rate and timing of repeat epinephrine dosing to determine the observation threshold at which the cumulative incidence of repeat epinephrine was less than 2% for every 1 h increase in observation time.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This multicentre, retrospective cohort study across 30 emergency departments in the USA and one emergency department in Canada included children aged 6 months to 17 years who, according to electronic medical records, presented to one of the participating emergency departments with an acute allergic reaction that was treated with intramuscular, subcutaneous, or intravenous epinephrine before arrival at the emergency department or in the emergency department between Jan 1, 2016, and Dec 31, 2019. We excluded patients who had no documentation of symptoms or examination findings before presenting to the emergency department, were transferred from outside health-care facilities, had reactions secondary to medications administered in the emergency department, or had comorbidities requiring tailored management decisions. Demographics, medical history, and emergency department revisits within 72 h of discharge were extracted from electronic medical records. The primary outcome was the time from first to last administration of epinephrine. For patients on intravenous epinephrine infusions, the relevant time interval was from infusion initiation to discontinuation. Kaplan–Meier analyses were used to compare time to last epinephrine dose by initial reaction severity, stratified by respiratory and cardiovascular involvement (no respiratory or cardiovascular involvement, respiratory but no cardiovascular involvement, and cardiovascular involvement).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Of 7717 patients with ICD-10 Clinical Modification codes for anaphylaxis, 5641 were eligible for inclusion (median age 7·9 years [IQR 3·3–13·1]; 2475 [43·9%] female; 3166 [56·1%] male). Of the 5139 patients who reported ethnicity, 1131 (22·0%) identified as Hispanic and 4008 (78·0%) identified as non-Hispanic. 263 (4·7%) of 5641 patients received a repeat epinephrine after 2 h of the first dose, whereas 109 (1·9%) received repeat epinephrine after 4 h, 64 (1·1%) after 6 h, and 46 (0·8%) after 8 h. The observation period at which the increase in cumulative incidence of repeat epinephrine was less than 2% was 115 min (95% CI 105–122) for all patients, 105 min (54–135) for patients without respiratory or cardiovascular involvement (n=1070), 109 min (98–118) for patients with respiratory but no cardiovascular involvement (n=4076), and 161 min (125–249) for patients with cardiov","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 7","pages":"Pages 484-496"},"PeriodicalIF":19.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, co-occurring psychiatric conditions, and sex differences in young people without intellectual impairment who are autistic, ADHD, or autistic–ADHD: a population-based cross-sectional study in Iceland","authors":"Kristin Ros Sigurdardottir MS ,&nbsp;Dagmar Kr Hannesdottir PhD ,&nbsp;Berglind Hauksdottir MS ,&nbsp;Prof Thomas H Ollendick PhD ,&nbsp;Katrin Davidsdottir MD ,&nbsp;Thorhildur Halldorsdottir PhD","doi":"10.1016/S2352-4642(25)00132-4","DOIUrl":"10.1016/S2352-4642(25)00132-4","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Population-based studies comparing the incidence and co-occurring psychiatric conditions of young people without intellectual impairment who are autistic, Attention-Deficit/Hyperactivity Disorder (ADHD), or autistic–ADHD are scarce. For autistic, ADHD, and autistic–ADHD youth in Iceland aged 7–18 years without intellectual impairment, we aimed primarily to estimate the age-standardised incidence of these 3 neurotypes, overall and by sex, and secondarily to estimate the prevalence of co-occurring psychiatric conditions and emotional and conduct challenges.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this nationwide, population-based cross-sectional study we included young people without intellectual impairment aged 7–18 years who were autistic, ADHD, or autistic–ADHD. Children were referred to the Centre for Child Development and Behaviour in Reykjavik, Iceland, through a structured pre-assessment process during which caregivers completed a validated screening battery on the child's behavioural, emotional, and developmental characteristics. Trained clinicians administered gold-standard clinical assessment procedures to assess autism, ADHD, and co-occurring psychiatric presentations. Caregiver-reported and teacher-reported emotional and conduct challenges were measured with the Strengths and Difficulties Questionnaire. ICD-10 condition classification was determined during consensus meetings with clinical psychologists and a paediatrician. Age-standardised prevalence and incidence rates were calculated.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Between Feb 11, 2013, and Dec 20, 2021, 2034 children age 7–18 years without intellectual impairment (728 females and 1306 males; mean age 10·93 [SD 2·82]) were recognised as autistic (n=229), ADHD (n=1428), or autistic–ADHD (n=377) in Iceland. Age-standardised incidence rates were 126 per 100 000 person-years (95% CI 116–137) for all autistic young people (ie, autistic and autistic–ADHD) and 374 per 100 000 person-years (357–392) for all young people with ADHD (ie, ADHD and autistic–ADHD). By neurotype groups, the incidence per 100 000 person-years was 48 (95% CI 42–54) for autism, 78 (71–87) for autism–ADHD, and 295 (280–311) for ADHD. Incidence was lower in females than males for all three neurotypes: incidence rate ratio 0·53 (95% CI 0·40–0·69) for autistic young people, 0·43 (0·35–0·54) for autistic–ADHD young people, and 0·64 (0·57–0·71) for ADHD young people.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;This study provides robust, population-based estimates of the incidence of autistic, ADHD, and autistic–ADHD young people without intellectual impairment. The higher incidence of autistic–ADHD young people compared with autistic alone underscores the common co-occurrence of ADHD in autistic young people—a pattern that might have been underrepresented in previous literature.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;None.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Translation&lt;/h3&gt;&lt;div&gt;For the Icelandic translati","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 7","pages":"Pages 459-469"},"PeriodicalIF":19.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Societal changes, children's play, and children's mental health","authors":"Peter Gray","doi":"10.1016/S2352-4642(25)00160-9","DOIUrl":"10.1016/S2352-4642(25)00160-9","url":null,"abstract":"","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 8","pages":"Pages 526-528"},"PeriodicalIF":19.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144289922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolved anaphylaxis in the emergency department: should I stay or should I go?","authors":"Marcus Shaker","doi":"10.1016/S2352-4642(25)00159-2","DOIUrl":"10.1016/S2352-4642(25)00159-2","url":null,"abstract":"","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 7","pages":"Pages 441-442"},"PeriodicalIF":19.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing paediatric cancer care in Jordan: a strategic 10-year roadmap","authors":"Rawad Rihani MD MSc ,&nbsp;Abdalla Awidi MD ,&nbsp;Maha Barbar MD ,&nbsp;Maher Mustafa MD ,&nbsp;Laila Tutunji MD ,&nbsp;Yaser Rayyan MD ,&nbsp;Asem Mansour MD ,&nbsp;Hikmat Abdel-Razeq MD ,&nbsp;Iyad Sultan MD","doi":"10.1016/S2352-4642(25)00103-8","DOIUrl":"10.1016/S2352-4642(25)00103-8","url":null,"abstract":"<div><div>In this Review, we assess the current landscape of paediatric cancer care in Jordan, identifying crucial gaps, barriers, and challenges in delivering optimal paediatric cancer services, and propose targeted, actionable solutions. We outline a comprehensive 10-year roadmap for advancing paediatric cancer care in Jordan, which was developed by national experts in paediatric oncology and public health. The roadmap emphasises a holistic, patient-centred approach that prioritises equitable, accessible, and high-quality care for children. Spanning the entire cancer care continuum, from early detection and diagnosis to treatment, survivorship, and palliative care, the roadmap emphasises psychosocial support for families. Key priorities include capacity building, standardised treatment regimens, and evidence-based practices, as well as community engagement to promote cancer awareness and reduce stigma. In this roadmap, we also highlight the need for innovative therapies, expanded research capacity, and workforce development to address the unique needs of children with cancer. A proposed consensus-driven monitoring system will ensure sustainable implementation and progress in paediatric oncology services in Jordan.</div></div><div><h3>Translation</h3><div>For the Arabic translation of the abstract see Supplementary Materials section.</div></div>","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 7","pages":"Pages 497-507"},"PeriodicalIF":19.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Child Adolesc Health 2025; 9: 383–92","authors":"","doi":"10.1016/S2352-4642(25)00164-6","DOIUrl":"10.1016/S2352-4642(25)00164-6","url":null,"abstract":"","PeriodicalId":54238,"journal":{"name":"Lancet Child & Adolescent Health","volume":"9 7","pages":"Page e15"},"PeriodicalIF":19.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}